Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Cancer Immunol Res. 2016 Jan 19;4(3):194–203. doi: 10.1158/2326-6066.CIR-15-0210

Figure 4. CD4+ T cell subsets with significant differences in biopsies on PD-1 blockade therapy.

Figure 4

(A) Dendogram illustrating all CD4+ T cells that present with a lower P value (P ≤ 0.05) with higher 95%CI using CytoAnalysis program. The program presents as positive values a decrease of the mean difference (MD) and the 95% CI of the baseline and post-dose samples as a positive value. (n) describes how many patients of the 18 paired TILs show that particular phenotype. (B) The percentage of a phenotype of T effector CD8-CD4+CD45RO+CD57+ T cells (*P = 0.05) plus two related more extended phenotypes, CD8-CD4+CD45RO+CCR7-CD57+ (*P = 0.003) and CD8−CD4+CD45RO+CCR7-CD62L-CD57+ (*P = 0.05). The on-going treatment (red circle) was compared between responder and non-responders tumors (right plot), being the P value: CD8-CD4+CD45RO+CD57+: * P = 0.024; CD8-CD4+CD45RO+CCR7-CD57+: *P = 0.022; and CD8-CD4+CD45RO+CCR7-CD62L-CD57+ (p>0.05)). B = before treatment; P = on anti–PD-1 therapy. Mean and ± SD are provided. Solid circles represent responders; open circles represent non-responders (n = 46 baseline; n = 37 treated).